Microdose therapy

• US 6,423,683 B1
• Filed: 07/11/2000
• Issued: 07/23/2002
• Est. Priority Date: 06/23/1997
• Status: Expired due to Fees

• Current Assignee: Queen's University At Kingston
• Original Assignee: Queen's University At Kingston
• Inventors: Adams, Michael A., Heaton, Jeremy P. W., Banting, James D.
• Primary Examiner(s): HENLEY III, RAYMOND J
• Application Number:
  US09/613,637
• Time in Patent Office: 742 Days
• Field of Search: 514/2, 514/192, 514/231.2, 514/470, 514/565, 514/668
• US Class Current: 514/13.5
• CPC Class Codes: A61K 31/04 Nitro compounds
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/21 Esters, e.g. nitroglycerine, selenocyanates
• CPC Class Codes: A61K 31/295 Iron group metal compounds
• CPC Class Codes: A61K 31/34 having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 38/063 Glutathione
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/02 for disorders of the vagina
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to {fraction (1/20)}) of those known to induce vasodilation in “normal” circulations. The low doses of these agents effectively alleviate vascular conditions associated with a reduction in NO production or an attenuation of NO effect, by restoring balance in vascular tone while exerting almost no systemic effect in normal vasculature.

Claims

1. A transdermal patch which releases an NO provider through the skin of an organism at a level which restores normal vascular tone to a local vascular bed exhibiting inappropriate vasoconstriction in the organism without inappropriately affecting systemic vascular tone of the organism.

2. The transdermal patch of claim 1 wherein the NO provider is released over a period of time less than 6 hours.

3. The transdermal patch of claim 1 wherein the NO provider is released over a period of time greater than 6 hours.

4. The transdermal patch of claim 1 wherein the level of NO provider released is about ½

to about {fraction (1/20)} of a concentration required to induce vasodilation in the local vascular bed of an organism not exhibiting inappropriate vasoconstriction.

5. The transdermal patch of claim 1 wherein the NO provider is selected from the group consisting of NO, CO, NO donors, CO donors, activators of guanylyl cyclase, PDE inhibitors, and substances which produce an effect equivalent to that of NO.

6. The transdermal patch of claim 5 wherein the NO provider is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, and N-hydroxy-L-arginine.

7. The transdermal patch of claim 6 wherein the NO provider is glyceryl trinitrate, and the level released results in a plasma concentration in the organism below about 250 pg/ml of glyceryl trinitrate.

8. The transdermal patch of claim 1 which restores normal vascular tone to a local vascular bed exhibiting inappropriate vasoconstriction associated with a reduction in NO production.

9. The transdermal patch of claim 1 which restores normal vascular tone to the pudendal or penile vasculature of a male with erectile dysfunction.

10. The transdermal patch of claim 1 which restores normal vascular tone to the pudendal, cervical or vaginal vasculature of a female with sexual dysfunction.

11. The transdermal patch of claim 10 wherein the sexual dysfunction in the female is insufficient vaginal lubrication, insufficient vaginal engorgement or dyspareunia.

12. A transdermal patch which releases an NO provider through the skin of an organism at a level of ½

to {fraction (1/20)} of the level required to induce vasodilation in normal circulation.

13. The transdermal patch of claim 12 wherein the NO provider is glyceryl trinitrate, and the level released results in a plasma concentration in the organism below about 250 pg/ml of glyceryl trinitrate.

14. A transdermal patch for treatment of sexual dysfunction and urogenital aging conditions which releases an NO provider at a level of ½

to {fraction (1/20)} of the level required to induce vasodilation in normal circulation.

15. The transdermal patch of claim 14 wherein the sexual dysfunction or urogenital aging condition comprises vaginal lubrication, vaginal engorgement, pain during intercourse, urogenital infections, and urogenitalia as affected by post-menopause, diabetes, vascular disease, estrogen depletion conditions, sexual dysfunction, and idiosyncratic vaginal dryness.

16. A method of treating male erectile dysfunction comprising administering to a patient suffering from male erectile dysfunction a phosphodiesterase inhibitor at a level which enhances NO and does not appreciably alter normal systemic vascular tone in the patient so that male erectile dysfunction is treated.

17. The method of claim 16 wherein the phosphodiesterase inhibitor is administered at a dose of ½

to {fraction (1/20)} of a concentration required to appreciably alter normal systemic vascular tone in the patient.

18. The method of claim 16 wherein the phosphodiesterase inhibitor is administered at a dose of ¼

to {fraction (1/20)} of a concentration required to appreciably alter normal systemic vascular tone in the patient.

19. The method of claim 16 wherein the phosphodiesterase inhibitor is administered at a dose of ⅛

to {fraction (1/16)} of a concentration required to appreciably alter normal systemic vascular tone in the patient.

20. The method of claim 16 wherein the phosphodiesterase inhibitor is administered orally, sublingually, buccally, intravenously, rectally, transdermally, via inhalation, enterally, parenterally, intracavernously, urethrally or intraurethrally.

21. The method of claim 16 wherein the phosphodiesterase inhibitor is administered orally.

22. The method of claim 16 wherein the phosphodiesterase inhibitor is administered intraurethrally.

23. A method of treating female sexual dysfunctions comprising administering to a patient suffering from a female sexual dysfunction a phosphodiesterase inhibitor so that the female sexual dysfunction is treated.

24. The method of claim 23 wherein the phosphodiesterase inhibitor is administered at a level which enhances NO and does not appreciably alter normal systemic vascular tone in the patient.

25. The method of claim 23 wherein the phosphodiesterase inhibitor is administered at a dose of ½

to {fraction (1/20)} of a concentration required to appreciably alter normal systemic vascular tone in the patient.

26. The method of claim 23 wherein the phosphodiesterase inhibitor is administered at a dose of ¼

to {fraction (1/20)} of a concentration required to appreciably alter normal systemic vascular tone in the patient.

27. The method of claim 23 wherein the phosphodiesterase inhibitor is administered at a dose of ⅛

to {fraction (1/16)} of a concentration required to appreciably alter normal systemic vascular tone in the patient.

28. The method of claim 23 wherein the phosphodiesterase inhibitor is administered orally, sublingually, buccally, intravenously, intravaginally, vaginally, rectally, transdermally, via inhalation, enterally, or parenterally.

29. The method of claim 23 wherein the phosphodiesterase inhibitor is administered orally.

30. The method of claim 23 wherein the female sexual dysfunction comprises insufficient vaginal lubrication, insufficient vaginal engorgement, pain during intercourse, dyspareunia, urogenital infections, or urogenitalia effects resulting from the group consisting of diabetes, vascular disease, estrogen depletion conditions and idiosyncratic vaginal dryness.

36. The method of claim 30 wherein the phosphodiesterase inhibitor is administered orally, sublingually, buccally, intravenously, vaginally, intravaginally, urethrally, intraurethrally, intracavernously, rectally, transdermally, via inhalation, enterally, or parenterally.

31. A method of treating Raynaud'"'"'s phenomenon comprising administering to a patient suffering from Raynaud'"'"'s phenomenon a phosphodiesterase inhibitor so that Raynaud'"'"'s phenomenon is treated.

32. The method of claim 31 wherein the phosphodiesterase inhibitor is administered at a level which enhances NO and does not appreciably alter normal systemic vascular tone in the patient.

33. The method of claim 31 wherein the phosphodiesterase inhibitor is administered at a dose of ½

to {fraction (1/20)} of a concentration required to appreciably alter normal systemic vascular tone in the patient.

34. The method of claim 31 wherein the phosphodiesterase inhibitor is administered at a dose of ¼

to {fraction (1/20)} of a concentration required to appreciably alter normal systemic vascular tone in the patient.

35. The method of claim 31 wherein the phosphodiesterase inhibitor is administered at a dose of ⅛

to {fraction (1/16)} of a concentration required to appreciably alter normal systemic vascular tone in the patient.